NCT05578300 Effective Translation of Endovascular Thrombectomy Trials Into Real-world Practice in the Asia-Pacific
| NCT ID | NCT05578300 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Ischemic Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2022-10-21 |
| Primary Completion | 2032-10-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2022-10-21 with a primary completion date of 2032-10-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
As a major breakthrough of acute stroke treatment over the past decade, endovascular thrombectomy (EVT) drastically improved neurological recovery and survival in patients with large vessel occlusion (LVO) ischemic strokes in major clinical trials. Nevertheless, much remained uncertain about the implementation of scientific evidence of EVT into real-world benefits. For instance, healthcare policies that influence critical time-matrices, endovascular thrombectomy techniques that may enhance success rate or prevent complications, or advanced imaging techniques that allow precise prognosis or expansion of treatment populations, should be evaluated. On the other hand, capturing LVO patients who were not able to undergo EVT may reveal the gap between clinical trials and real-world practice in the Asia-Pacific. In this multicenter prospective collaboration across the Asian-Pacific, the investigators aim to evaluate the determinants of effective EVT in the real-world setting.
Eligibility Criteria
Inclusion Criteria: * Patient who are over 18 years of age. * Patient with ischemic stroke with suspected large vessel occlusion (LVO), defined as occlusion of the internal carotid artery (ICA), M1 or M2 segment of the middle cerebral artery (MCA), or basilar artery (BA). Exclusion Criteria: * Patient with isolated vertebral artery occlusion not involving the BA.
Contact & Investigator
Bonaventure Yiu Ming IP, MB ChB
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT05578300 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05578300 currently recruiting?
Yes, NCT05578300 is actively recruiting participants. Contact the research team at bonaventureip@cuhk.edu.hk for enrollment information.
Where is the NCT05578300 trial being conducted?
This trial is being conducted at Linyi, China, Qingdao, China, Hong Kong, Hong Kong.
Who is sponsoring the NCT05578300 clinical trial?
NCT05578300 is sponsored by Chinese University of Hong Kong. The principal investigator is Bonaventure Yiu Ming IP, MB ChB at Chinese University of Hong Kong. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.